Clinical Trial Update: A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the efficacy and safety of HMI-115 in men with androgenetic alopecia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• HMI-115

Snippet

Sponsor: Hope Medicine (Nanjing) Co., Ltd | Conditions: Androgenetic Alopecia | Phase 2 | Status: COMPLETED